Skip to main content

National Lung Matrix Trial (NLMT)

In this UK-based umbrella trial, advanced non-small-cell lung cancer patients are stratified on the basis of the molecular genotype of the tumor and allocated to the appropriate targeted therapy, of which there are currently eight available.

The first results were presented at WCLC 2019:

Title: National Lung Matrix Trial (NLMT): First results from an umbrella phase II trial in advanced non-small cell lung cancer (NSCLC)
Presenter: Gary Middleton, University of Birmingham, UK
Monday, September 9: 09:20–09:30 (Abstract PL02.09)

Back to the WCLC 2019 conference hub